Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting 2024
Akero Therapeutics, Inc. (AKRO): A Visionary Small-Cap Stock Pick by Hedge Funds
Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference
Akero Therapeutics CDO Sells Shares Worth Over $230,000
H.C. Wainwright Maintains Akero Therapeutics(AKRO.US) With Buy Rating, Maintains Target Price $50
H.C. Wainwright analyst Ed Arce maintains $Akero Therapeutics(AKRO.US)$ with a buy rating, and maintains the target price at $50.According to TipRanks data, the analyst has a success rate of 44.0%
Oxford Industries Reports Weak Results, Joins Viper Energy And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Wellington Management Group LLP's Strategic Acquisition in Akero Therapeutics Inc
Akero Therapeutics' Promising Phase 3 Programs Bolster Buy Rating
Express News | Akero Therapeutics Inc - Phase 2B Symmetry Study Results Expected in Q1 2025
Express News | Akero Therapeutics Announces First Patient Dosed in Phase 3 Synchrony Outcomes Study of Efruxifermin in Patients With Compensated Cirrhosis Due to Mash
Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients With Compensated Cirrhosis Due to MASH
Akero Therapeutics, Inc. (AKRO): This Small-Cap Healthcare Stock Is A Good Buy Right Now
Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
Akero Therapeutics Insider Sold Shares Worth $386,714, According to a Recent SEC Filing
Insiders At Akero Therapeutics Sold US$1.1m In Stock, Alluding To Potential Weakness
Morgan Stanley Maintains Akero Therapeutics(AKRO.US) With Buy Rating, Maintains Target Price $46
Morgan Stanley analyst Michael Ulz maintains $Akero Therapeutics(AKRO.US)$ with a buy rating, and maintains the target price at $46.According to TipRanks data, the analyst has a success rate of 41.5%
Akero Therapeutics (AKRO) Receives a Buy From Morgan Stanley
Akero Therapeutics (AKRO) Gets a Buy From Evercore ISI
HC Wainwright & Co. Reiterates Buy on Akero Therapeutics, Maintains $50 Price Target
Akero Therapeutics Analyst Ratings